Trial reportClinical research in cardiology : official journal of the German Cardiac Society2015
Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation.
Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Aorticorenal Ganglion Ablation Enhances Blood Pressure Reduction After Renal Denervation.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Trial
- Skin sodium content as a predictor of blood pressure response to renal denervation.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Both coiling and clipping induce the time-dependent release of endogenous neuropeptide Y into serum.Frontiers in neurology · 2023Article
- Neuropeptide Y protects kidney from acute kidney injury by inactivating M1 macrophages via the Y1R-NF-κB-Mincle-dependent mechanism.International journal of biological sciences · 2023Article
- A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Article
- Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021Article
- Update on the Relationship Between Depression and Neuroendocrine Metabolism.Frontiers in neuroscience · 2021Review
- Neuropeptide Y and Metabolism Syndrome: An Update on Perspectives of Clinical Therapeutic Intervention Strategies.Frontiers in cell and developmental biology · 2021Review
- A role for NPY-NPY2R signaling in albuminuric kidney disease.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Renal Denervation: Is It Ready for Prime Time?Current cardiology reports · 2019Review
- Modulation of renal sympathetic innervation: recent insights beyond blood pressure control.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2018Review
- Erythrocyte Salt Sedimentation Assay Does Not Predict Response to Renal Denervation.Frontiers in medicine · 2018Article
- Second denervation in a patient with resistant hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Renal sympathetic denervation in therapy resistant hypertension - pathophysiological aspects and predictors for treatment success.World journal of cardiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal sympathetic denervation (RSD) represents a safe and effective treatment option for certain patients with resistant hypertension and has been shown to decrease sympathetic activity. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. The aim of the present study was to examine the effect of RSD on NPY and to analyze the association between changes in NPY levels and blood pressure reduction after RSD.
methodsA total of 150 consecutive patients (age 64.9 ± 10.2 years) from three clinical centers undergoing RSD were included in this study. Response to RSD was defined as an office systolic blood pressure (SBP) reduction of >10 mmHg 6 months after RSD. Venous blood samples for measurement of NPY were collected prior to and 6 months after RSD.
resultsBP and NPY levels were significantly reduced by 23/9 mmHg (p = 0.001/0.001) and 0.24 mg/dL (p < 0.01) 6 months after RSD. There was a significant correlation between baseline SBP- and RSD-related systolic BP reduction (r = -0.43; p < 0.001) and between serum NPY baseline values and NPY level changes (r = -0.52; p < 0.001) at the 6-month follow-up. The BP response to RSD (>10 mmHg) was associated with a significantly greater reduction in NPY level when compared with BP non-responders (p = 0.001).
conclusionThis study demonstrates an effect of RSD on serum NPY levels, a specific marker for sympathetic activity. The association between RSD-related changes in SBP and NPY levels provides further evidence of the effect of RSD on the sympathetic nervous system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.